Liqun Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Liqun Zhou has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
- Sidi Chen
Department of Genetics, Yale University School of Medicine, New haven, CT, USA
9 shared publications - Rong Fan
Department of Biomedical Engineering, Yale University, New Haven, CT 06520, USA
6 shared publications - Shan Xin
Department of Genetics, Yale School of Medicine, New Haven, USA
6 shared publications - Chuanpeng Dong
Department of Genetics, Yale University School of Medicine, New Haven, Connecticut
5 shared publications - Daniyal Mirza
Department of Genetics, Yale University School of Medicine, New Haven, Connecticut
5 shared publications - Emily He
Department of Genetics, Yale University School of Medicine, New Haven, Connecticut
5 shared publications
Latest Publications
- 4 November 2026
- Published by Springer Nature in Nature
In vivo CAR-T double knockout screen maps synergistic antitumour gene pairs
- 4 November 2026
- Published by Springer Nature in Nature
In vivo CAR-T double knockout screen maps synergistic antitumour gene pairs
- 13 July 2026
- Published by Springer Nature in Nature
- Vol. 656 (8126) , E2
Author Correction: OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumours
- 13 July 2026
- Published by Springer Nature in Nature
- Vol. 656 (8126) , E2
Author Correction: OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumours
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S21 from Rational Design of Immune Gene Therapy Combinations via In Vivo CRISPR Activation Screen of Tumor Microenvironment Modulators
Figure S1. AAV-CRISPRa-APCM approach as a cancer immunotherapy. Figure S2. Dual-AAV-CRISPRa-APCM approach as a cancer immunotherapy. Figure S3. Quality control of the APCM CRISPR activation screen in the E0771 lung metastasis model. Figure S4. AAV-mediated ORF delivery of immunostimulatory factors elicited antitumor responses. Figure S5. Validation of the six-gene combination CLCG4I in the E0771 metastatic tumor model. Figure S6. Evaluation of IL-12 and IL-23 formation in vitro and in vivo following AAVIL12B treatment. Figure S7. Safety evaluation of AAV-4II treatment. Figure S8. AAV-mediated ORF delivery of immunostimulatory molecules promotes immune cell infiltration into the TME. Figure S9. Gating strategy for analyzing tumor-infiltrating immune cell populations. Figure S10. Comparison of pathway enrichment for the bulk RNA-seq data for tumor cells. Figure S11. Comparison of pathway enrichment in tumor cells between AAV-4II and IFNG from the bulk RNA-seq dataset. Figure S12. Comparative transcriptomic analysis of tumor-infiltrating OT-I T cells across AAV treatment groups. Figure S13. Single-cell transcriptomic profiling reveals 4II-induced transcriptional reprogramming of lung-infiltrating T cells. Figure S14. Cell-cell communication and ligand-receptor interaction analysis in AAV-4II treated tumors. Figure S15. CCL and CXCL signaling pathway network following AAV-4II treatment. Figure S16. Ectopic expression of immunostimulatory factors synergizes with human CART cells. Figure S17. Combining AAV-4II with CAR-T cell enhances anti-tumor activity in human tumor models. Figure S18. Signature gene expression in CD8+ CAR-T cells, comparing 4II vs control groups. Figure S19. Differential pathways in CD8+ CAR-T cells, comparing 4II vs control groups. Figure S20. Elevated 4II signature expression is associated with immunotherapy response. Figure S21. Impact of 4II gene signatures on human patient survival in cancer immunotherapy treatment settings.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S21 from Rational Design of Immune Gene Therapy Combinations via In Vivo CRISPR Activation Screen of Tumor Microenvironment Modulators
Figure S1. AAV-CRISPRa-APCM approach as a cancer immunotherapy. Figure S2. Dual-AAV-CRISPRa-APCM approach as a cancer immunotherapy. Figure S3. Quality control of the APCM CRISPR activation screen in the E0771 lung metastasis model. Figure S4. AAV-mediated ORF delivery of immunostimulatory factors elicited antitumor responses. Figure S5. Validation of the six-gene combination CLCG4I in the E0771 metastatic tumor model. Figure S6. Evaluation of IL-12 and IL-23 formation in vitro and in vivo following AAVIL12B treatment. Figure S7. Safety evaluation of AAV-4II treatment. Figure S8. AAV-mediated ORF delivery of immunostimulatory molecules promotes immune cell infiltration into the TME. Figure S9. Gating strategy for analyzing tumor-infiltrating immune cell populations. Figure S10. Comparison of pathway enrichment for the bulk RNA-seq data for tumor cells. Figure S11. Comparison of pathway enrichment in tumor cells between AAV-4II and IFNG from the bulk RNA-seq dataset. Figure S12. Comparative transcriptomic analysis of tumor-infiltrating OT-I T cells across AAV treatment groups. Figure S13. Single-cell transcriptomic profiling reveals 4II-induced transcriptional reprogramming of lung-infiltrating T cells. Figure S14. Cell-cell communication and ligand-receptor interaction analysis in AAV-4II treated tumors. Figure S15. CCL and CXCL signaling pathway network following AAV-4II treatment. Figure S16. Ectopic expression of immunostimulatory factors synergizes with human CART cells. Figure S17. Combining AAV-4II with CAR-T cell enhances anti-tumor activity in human tumor models. Figure S18. Signature gene expression in CD8+ CAR-T cells, comparing 4II vs control groups. Figure S19. Differential pathways in CD8+ CAR-T cells, comparing 4II vs control groups. Figure S20. Elevated 4II signature expression is associated with immunotherapy response. Figure S21. Impact of 4II gene signatures on human patient survival in cancer immunotherapy treatment settings.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Rational Design of Immune Gene Therapy Combinations via In Vivo CRISPR Activation Screen of Tumor Microenvironment Modulators
The hostile tumor microenvironment (TME) remains a major challenge for cancer immunotherapy. In this study, we performed TME-targeted in vivo CRISPR activation (CRISPRa) screen to identify factors that promote antitumor immunity, culminating in rationally designed immune gene therapy combinations. Multiplexed activation of genes encoding antigen presentation, T-cell proliferation, costimulation, and migration (APCM) leads to enhanced antitumor responses. An APCM-focused CRISPRa screen in metastatic tumors identified Cd80, Tnfsf14, Cxcl10, Tnfsf18, Tnfsf9, and Ifng as top immunostimulatory candidates. Further optimization pinpointed Tnfsf9 (4-1BBL) + Ifng + Il12b (4II) as a potent therapeutic combination. Adeno-associated virus (AAV) 4II enhanced antigen presentation, T-cell activation, proliferation, cytotoxicity, and tumor infiltration. Preconditioning the TME with AAV-4II synergized with chimeric antigen receptor (CAR) and T-cell receptor (TCR) T-cell therapies to suppress primary and metastatic solid tumors in vivo. These findings establish TME-targeted CRISPRa screening as a rapid route to develop immune gene therapy combinations against solid tumors.Significance:By leveraging TME-focused in vivo CRISPRa screening, we identified immunomodulatory genes for rational AAV-based combinations that boost antitumor immunity. The optimized three-gene cocktail (4II) enhances antigen presentation and T-cell function and synergizes with adoptive T-cell therapies to improve immunotherapy efficacy in solid tumors and metastases.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Rational Design of Immune Gene Therapy Combinations via In Vivo CRISPR Activation Screen of Tumor Microenvironment Modulators
The hostile tumor microenvironment (TME) remains a major challenge for cancer immunotherapy. In this study, we performed TME-targeted in vivo CRISPR activation (CRISPRa) screen to identify factors that promote antitumor immunity, culminating in rationally designed immune gene therapy combinations. Multiplexed activation of genes encoding antigen presentation, T-cell proliferation, costimulation, and migration (APCM) leads to enhanced antitumor responses. An APCM-focused CRISPRa screen in metastatic tumors identified Cd80, Tnfsf14, Cxcl10, Tnfsf18, Tnfsf9, and Ifng as top immunostimulatory candidates. Further optimization pinpointed Tnfsf9 (4-1BBL) + Ifng + Il12b (4II) as a potent therapeutic combination. Adeno-associated virus (AAV) 4II enhanced antigen presentation, T-cell activation, proliferation, cytotoxicity, and tumor infiltration. Preconditioning the TME with AAV-4II synergized with chimeric antigen receptor (CAR) and T-cell receptor (TCR) T-cell therapies to suppress primary and metastatic solid tumors in vivo. These findings establish TME-targeted CRISPRa screening as a rapid route to develop immune gene therapy combinations against solid tumors.Significance:By leveraging TME-focused in vivo CRISPRa screening, we identified immunomodulatory genes for rational AAV-based combinations that boost antitumor immunity. The optimized three-gene cocktail (4II) enhances antigen presentation and T-cell function and synergizes with adoptive T-cell therapies to improve immunotherapy efficacy in solid tumors and metastases.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Rational Design of Immune Gene Therapy Combinations via In Vivo CRISPR Activation Screen of Tumor Microenvironment Modulators
Next-generation sequencing datasets, including CRISPR screens, bulk RNA-seq, single-cell RNA-seq, and datasets related to adoptive cell therapy (ACT) and immune checkpoint blockade (ICB).
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Rational Design of Immune Gene Therapy Combinations via In Vivo CRISPR Activation Screen of Tumor Microenvironment Modulators
Next-generation sequencing datasets, including CRISPR screens, bulk RNA-seq, single-cell RNA-seq, and datasets related to adoptive cell therapy (ACT) and immune checkpoint blockade (ICB).
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Rational Design of Immune Gene Therapy Combinations via In Vivo CRISPR Activation Screen of Tumor Microenvironment Modulators
Source data and statistical analyses for in vivo and in vitro experiments.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Rational Design of Immune Gene Therapy Combinations via In Vivo CRISPR Activation Screen of Tumor Microenvironment Modulators
Source data and statistical analyses for in vivo and in vitro experiments.
- 27 February 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (6) , 1222-1244
Rational Design of Immune Gene Therapy Combinations via In Vivo CRISPR Activation Screen of Tumor Microenvironment Modulators
The hostile tumor microenvironment (TME) remains a major challenge for cancer immunotherapy. In this study, we performed TME-targeted in vivo CRISPR activation (CRISPRa) screen to identify factors that promote antitumor immunity, culminating in rationally designed immune gene therapy combinations. Multiplexed activation of genes encoding antigen presentation, T-cell proliferation, costimulation, and migration (APCM) leads to enhanced antitumor responses. An APCM-focused CRISPRa screen in metastatic tumors identified Cd80, Tnfsf14, Cxcl10, Tnfsf18, Tnfsf9, and Ifng as top immunostimulatory candidates. Further optimization pinpointed Tnfsf9 (4-1BBL) + Ifng + Il12b (4II) as a potent therapeutic combination. Adeno-associated virus (AAV) 4II enhanced antigen presentation, T-cell activation, proliferation, cytotoxicity, and tumor infiltration. Preconditioning the TME with AAV-4II synergized with chimeric antigen receptor (CAR) and T-cell receptor (TCR) T-cell therapies to suppress primary and metastatic solid tumors in vivo. These findings establish TME-targeted CRISPRa screening as a rapid route to develop immune gene therapy combinations against solid tumors. Significance: By leveraging TME-focused in vivo CRISPRa screening, we identified immunomodulatory genes for rational AAV-based combinations that boost antitumor immunity. The optimized three-gene cocktail (4II) enhances antigen presentation and T-cell function and synergizes with adoptive T-cell therapies to improve immunotherapy efficacy in solid tumors and metastases.
- 27 February 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (6) , 1222-1244
Rational Design of Immune Gene Therapy Combinations via In Vivo CRISPR Activation Screen of Tumor Microenvironment Modulators
The hostile tumor microenvironment (TME) remains a major challenge for cancer immunotherapy. In this study, we performed TME-targeted in vivo CRISPR activation (CRISPRa) screen to identify factors that promote antitumor immunity, culminating in rationally designed immune gene therapy combinations. Multiplexed activation of genes encoding antigen presentation, T-cell proliferation, costimulation, and migration (APCM) leads to enhanced antitumor responses. An APCM-focused CRISPRa screen in metastatic tumors identified Cd80, Tnfsf14, Cxcl10, Tnfsf18, Tnfsf9, and Ifng as top immunostimulatory candidates. Further optimization pinpointed Tnfsf9 (4-1BBL) + Ifng + Il12b (4II) as a potent therapeutic combination. Adeno-associated virus (AAV) 4II enhanced antigen presentation, T-cell activation, proliferation, cytotoxicity, and tumor infiltration. Preconditioning the TME with AAV-4II synergized with chimeric antigen receptor (CAR) and T-cell receptor (TCR) T-cell therapies to suppress primary and metastatic solid tumors in vivo. These findings establish TME-targeted CRISPRa screening as a rapid route to develop immune gene therapy combinations against solid tumors. Significance: By leveraging TME-focused in vivo CRISPRa screening, we identified immunomodulatory genes for rational AAV-based combinations that boost antitumor immunity. The optimized three-gene cocktail (4II) enhances antigen presentation and T-cell function and synergizes with adoptive T-cell therapies to improve immunotherapy efficacy in solid tumors and metastases.
- Top Cited Papers
- 25 February 2026
- Published by Springer Nature in Nature
- Vol. 652 (8110) , 740-751
OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumours
Chimeric antigen receptor (CAR)-natural killer (NK) cell therapies hold promise for solid tumours but remain limited because of poor tumour infiltration, persistence and resistance in the tumour microenvironment1-4. Here, to identify gain-of-function targets that enhance CAR-NK cell efficacy, we performed an unbiased in vivo CRISPR activation screen followed by a barcoded targeted in vivo open reading frame screen in primary human CAR-NK cells. We identified and comprehensively validated OR7A10, a G protein-coupled receptor (GPCR), as the top candidate. Engineering CAR-NK cells with OR7A10 cDNA (a CRISPR-independent method with a simple manufacturing strategy) enhanced their proliferation, activation, degranulation, cytokine production, death ligand expression, chemokine receptor expression, cytotoxicity, persistence, metabolic fitness and tumour microenvironment resistance. Moreover, exhaustion in primary human NK cells derived from multiple peripheral blood and cord blood donors was reduced. OR7A10 gain-of-function CAR-NK cells displayed strong in vivo efficacy across multiple solid tumour models. For example, 100% complete response with long-term tumour control and survival benefit in an orthotopic breast cancer mouse model were achieved. These findings establish OR7A10-engineered CAR-NK cells as a highly potent and scalable off-the-shelf therapeutic for solid tumours.
- 25 February 2026
- Published by Springer Nature in Nature
- Vol. 652 (8110) , 740-751
Top Cited PapersOR7A10 GPCR engineering boosts CAR-NK therapy against solid tumours
Chimeric antigen receptor (CAR)-natural killer (NK) cell therapies hold promise for solid tumours but remain limited because of poor tumour infiltration, persistence and resistance in the tumour microenvironment1-4. Here, to identify gain-of-function targets that enhance CAR-NK cell efficacy, we performed an unbiased in vivo CRISPR activation screen followed by a barcoded targeted in vivo open reading frame screen in primary human CAR-NK cells. We identified and comprehensively validated OR7A10, a G protein-coupled receptor (GPCR), as the top candidate. Engineering CAR-NK cells with OR7A10 cDNA (a CRISPR-independent method with a simple manufacturing strategy) enhanced their proliferation, activation, degranulation, cytokine production, death ligand expression, chemokine receptor expression, cytotoxicity, persistence, metabolic fitness and tumour microenvironment resistance. Moreover, exhaustion in primary human NK cells derived from multiple peripheral blood and cord blood donors was reduced. OR7A10 gain-of-function CAR-NK cells displayed strong in vivo efficacy across multiple solid tumour models. For example, 100% complete response with long-term tumour control and survival benefit in an orthotopic breast cancer mouse model were achieved. These findings establish OR7A10-engineered CAR-NK cells as a highly potent and scalable off-the-shelf therapeutic for solid tumours.
- Open Access
- 20 March 2025
- Published by Springer Nature in Nature Biomedical Engineering
- Vol. 9 (8) , 1290-1308
Cas12a-knock-in mice for multiplexed genome editing, disease modelling and immune-cell engineering
The pleiotropic effects of human disease and the complex nature of gene-interaction networks require knock-in mice allowing for multiplexed gene perturbations. Here we describe a series of knock-in mice with a C57BL/6 background and with the conditional or constitutive expression of LbCas12a or of high-fidelity enhanced AsCas12a, which were inserted at the Rosa26 locus. The constitutive expression of Cas12a in the mice did not lead to discernible pathology and enabled efficient multiplexed genome engineering. We used the mice for the retrovirus-based immune-cell engineering of CD4+ and CD8+ T cells, B cells and bone-marrow-derived dendritic cells, for autochthonous cancer modelling through the delivery of multiple CRISPR RNAs as a single array using adeno-associated viruses, and for the targeted genome editing of liver tissue using lipid nanoparticles. We also describe a system for simultaneous dual-gene activation and knockout (DAKO). The Cas12a-knock-in mice and the viral and non-viral delivery vehicles provide a versatile toolkit for ex vivo and in vivo applications in genome editing, disease modelling and immune-cell engineering, and for the deconvolution of complex gene interactions.
- 20 March 2025
- Published by Springer Nature in Nature Biomedical Engineering
- Vol. 9 (8) , 1290-1308
Open AccessCas12a-knock-in mice for multiplexed genome editing, disease modelling and immune-cell engineering
The pleiotropic effects of human disease and the complex nature of gene-interaction networks require knock-in mice allowing for multiplexed gene perturbations. Here we describe a series of knock-in mice with a C57BL/6 background and with the conditional or constitutive expression of LbCas12a or of high-fidelity enhanced AsCas12a, which were inserted at the Rosa26 locus. The constitutive expression of Cas12a in the mice did not lead to discernible pathology and enabled efficient multiplexed genome engineering. We used the mice for the retrovirus-based immune-cell engineering of CD4+ and CD8+ T cells, B cells and bone-marrow-derived dendritic cells, for autochthonous cancer modelling through the delivery of multiple CRISPR RNAs as a single array using adeno-associated viruses, and for the targeted genome editing of liver tissue using lipid nanoparticles. We also describe a system for simultaneous dual-gene activation and knockout (DAKO). The Cas12a-knock-in mice and the viral and non-viral delivery vehicles provide a versatile toolkit for ex vivo and in vivo applications in genome editing, disease modelling and immune-cell engineering, and for the deconvolution of complex gene interactions.
- Top Cited PapersOpen Access
- 25 November 2022
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 378 (6622) , 872-+
Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has highlighted the need for vaccines that not only prevent disease but also prevent transmission. Parenteral vaccines induce robust systemic immunity but poor immunity at the respiratory mucosa. We developed a vaccine strategy that we call “prime and spike,” which leverages existing immunity generated by primary vaccination (prime) to elicit mucosal immune memory within the respiratory tract by using unadjuvanted intranasal spike boosters (spike). We show that prime and spike induces robust resident memory B and T cell responses, induces immunoglobulin A at the respiratory mucosa, boosts systemic immunity, and completely protects mice with partial immunity from lethal SARS-CoV-2 infection. Using divergent spike proteins, prime and spike enables the induction of cross-reactive immunity against sarbecoviruses.
- 25 November 2022
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 378 (6622) , 872-+
Top Cited PapersOpen AccessUnadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has highlighted the need for vaccines that not only prevent disease but also prevent transmission. Parenteral vaccines induce robust systemic immunity but poor immunity at the respiratory mucosa. We developed a vaccine strategy that we call “prime and spike,” which leverages existing immunity generated by primary vaccination (prime) to elicit mucosal immune memory within the respiratory tract by using unadjuvanted intranasal spike boosters (spike). We show that prime and spike induces robust resident memory B and T cell responses, induces immunoglobulin A at the respiratory mucosa, boosts systemic immunity, and completely protects mice with partial immunity from lethal SARS-CoV-2 infection. Using divergent spike proteins, prime and spike enables the induction of cross-reactive immunity against sarbecoviruses.